MOSCOW (August 11) RIA Novosti – An Ebola vaccine co-developed by GlaxoSmithKline (GSK) and US scientists has shown promising results on animals and is to enter the first stage of testing on humans if approved by US Food and Drug Administration, ABC News reported Monday.
A GSK official saidSunday that "it is right at the beginning of the development journey and still has a very long way to go,” without giving a specific timeline for the development and approval of the medicine, ABC News reported Monday.
The US National Institute of Allergy and Infectious Diseases (NIAID) is also supporting work on early-stage Ebola vaccines from the Johnson & Johnson pharmaceuticaldeveloper. The early- stage vaccine is expected to enter the first stage of clinical testing in late 2015 or early 2016, ABC News further reported.
The West African outbreak of Ebola virus disease (EVD), which has no known cure, was declared an international public health emergency by the UN on Friday.
“I am declaring the current outbreak of the Ebola Virus Disease [in Guinea, Liberia, and Sierra Leone that has now spread to Nigeria] a public health emergency of international concern,” World Health Organization (WHO) Director-General Dr. Margaret Chan told a press conference in Geneva on Friday. TheWHO now expects the number of cases to rise.
In the meantime,aid workers returning to the US from working with Ebola victims in West Africa will be kept in quarantine as a precaution,the North Carolina Department of Health and Human Services reported Sunday.
Keiji Fukuda, WHO assistant director-general for health security, reported1,825 infected people on Sunday, with a 55-60% mortality rate, adding that “what is difficult in this situation is that we are dealing with countries with weak health systems.”